Fig. 8.

Schematic diagram of degraded the BCR/ABL oncoprotein by Ab@Tf-Cou6-PLGA NPs. The anti-BCR/ABL antibodies were loaded into nanoparticles, and the transferrin was modified on the surface of Ab@Cou6-PLGA NPs to increase the CML targeting ability. The Ab@Tf-Cou6-PLGA NPs could deliver anti-BCR/ABL antibodies into CML cells. In the acidic environment of the lysosome of CML cells, the Ab@Tf-Cou6-PLGA NPs were degraded and the anti-BCR/ABL antibodies were released. The anti-BCR/ABL antibodies can specifically bind to the BCR/ABL oncoprotein and degrade the BCR/ABL protein via the Trim-Away pathway